Search

EHA Statement on the Erasmus MC Attack

EHA is deeply saddened and appalled by the news of the twin shootings in Rotterdam, the Netherlands. We condemn these senseless acts of violence in the strongest possible terms.

Read more

Immune Therapies for Hematologic Disorders

Recently the treatment of hematological and solid malignancies has been revolutionized by the introduction of novel immunotherapeutic strategies.

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more

Pivotal Ruxolitinib Data Shows Promise for Patients with PV.

 

Polycythemia vera (PV) is a chronic, incurable blood cancer with limited treatment options. If uncontrolled, PV can cause serious cardiovascular complications, such as stroke and heart attack.

Read more

EHA-LSHBT Virtual Hematology Updates, a Successful Course Tailored for the Region!

March – October 2021

In a series of six webinar courses chairs Gianluca Gaidano (EHA) and Ali Taher (LSHBT) were joined by several experts that gave lectures and interactive patient cases to practitioners who manage patients with benign and hematologic malignancies.…

Read more

Meeting program

Thursday, October 12*All times are in EET.

Read more

EHA Bilateral Collaborative Grant

The call for applications is closed.

Read more